Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Iovance Biotherapeutics, Inc. - Common Stock (NQ:IOVA)

2.230 -0.110 (-4.70%)
Official Closing Price Updated: 4:00 PM EDT, Jul 18, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 14,748,061
Open 2.390
Bid (Size) 2.230 (4)
Ask (Size) 2.290 (4)
Prev. Close 2.340
Today's Range 2.220 - 2.479
52wk Range 1.639 - 12.51
Shares Outstanding 305,252,194
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
IOVANCE INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Iovance Biotherapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire

Performance

YTD
-71.4%
-71.4%
1 Month
+9.3%
+9.3%
3 Month
-27.6%
-27.6%
6 Month
-62.3%
-62.3%
1 Year
-73.2%
-73.2%

More News

Read More
Simulations Plus, FB Financial And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Via Benzinga
Iovance Biotherapeutics Appoints Corleen Roche as Chief Financial Officer
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Iovance Biotherapeutics
From Faruqi & Faruqi, LLP
Via Business Wire
FINAL IOVANCE DEADLINE ALERT: Bragar Eagel & Squire, P.C. Urges Investors in Iovance Biotheapeutics, Inc. (IOVA) to Inquire About Their Rights in Class Action Lawsuit
From Bragar Eagel & Squire
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Iovance Biotherapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - IOVA
From Pomerantz LLP
Via GlobeNewswire
Class Action Filed Against Iovance Biotherapeutics, Inc. (IOVA) - July 14, 2025 Deadline to Join - Contact Levi & Korsinsky
Via NewMediaWire
Topics Fraud Lawsuit
Class Action Filed Against Iovance Biotherapeutics, Inc. (IOVA) - July 14, 2025 Deadline to Join - Contact Levi & Korsinsky
Via TheNewswire.com
Topics Fraud Lawsuit
Real-World Data Demonstrate a 49% Response Rate for Commercial Amtagvi® in Patients with Advanced Melanoma
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
IOVANCE DEADLINE ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Iovance Biotherapeutics, Inc. and Urgently Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
IOVA Deadline: Rosen Law Firm Urges Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights
From The Rosen Law Firm, P.A.
Via Business Wire
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Iovance Biotherapeutics
From Faruqi & Faruqi LLP
Via GlobeNewswire
July 14, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against IOVA
Via NewMediaWire
Topics Fraud Lawsuit
July 14, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against IOVA
Via TheNewswire.com
Topics Fraud Lawsuit
Iovance Biotherapeutics Appoints Marc R. Theoret, M.D. as Senior Vice President, Regulatory Strategy
From Iovance Biotherapeutics, Inc.
Via GlobeNewswire
Investors in Iovance Biotherapeutics, Inc. Should Contact Levi & Korsinsky Before July 14, 2025 to Discuss Your Rights - IOVA
Via NewMediaWire
Topics Fraud Lawsuit
Investors in Iovance Biotherapeutics, Inc. Should Contact Levi & Korsinsky Before July 14, 2025 to Discuss Your Rights - IOVA
Via TheNewswire.com
Topics Fraud Lawsuit
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Iovance Biotherapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - IOVA
From Pomerantz LLP
Via GlobeNewswire
Iovance Biotherapeutics, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before July 14, 2025 to Discuss Your Rights - IOVA
Via NewMediaWire
Topics Fraud Lawsuit
Iovance Biotherapeutics, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before July 14, 2025 to Discuss Your Rights - IOVA
Via TheNewswire.com
Topics Fraud Lawsuit
IOVA LAWSUIT ALERT: Levi & Korsinsky Notifies Iovance Biotherapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
Via TheNewswire.com
Topics Fraud Lawsuit
IOVA LAWSUIT ALERT: Levi & Korsinsky Notifies Iovance Biotherapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
Via NewMediaWire
Topics Fraud Lawsuit
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Krispy Kreme, Strategy Incorporated, Organon, and Iovance and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of July 14, 2025 in Iovance Lawsuit - IOVA
Via NewMediaWire
Topics Fraud Lawsuit

Frequently Asked Questions

Is Iovance Biotherapeutics, Inc. - Common Stock publicly traded?
Yes, Iovance Biotherapeutics, Inc. - Common Stock is publicly traded.
What exchange does Iovance Biotherapeutics, Inc. - Common Stock trade on?
Iovance Biotherapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Iovance Biotherapeutics, Inc. - Common Stock?
The ticker symbol for Iovance Biotherapeutics, Inc. - Common Stock is IOVA on the Nasdaq Stock Market
What is the current price of Iovance Biotherapeutics, Inc. - Common Stock?
The current price of Iovance Biotherapeutics, Inc. - Common Stock is 2.230
When was Iovance Biotherapeutics, Inc. - Common Stock last traded?
The last trade of Iovance Biotherapeutics, Inc. - Common Stock was at 07/18/25 04:00 PM ET
What is the market capitalization of Iovance Biotherapeutics, Inc. - Common Stock?
The market capitalization of Iovance Biotherapeutics, Inc. - Common Stock is 680.71M
How many shares of Iovance Biotherapeutics, Inc. - Common Stock are outstanding?
Iovance Biotherapeutics, Inc. - Common Stock has 681M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.